X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in T-cell, B-cell, and natural ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

The Rome-based charity recently applied for marketing authorization of the same gene therapy, previously advanced by Orchard Therapeutics, in the EU.

CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announced it will be presenting next week at Terrapinn’s Advanced Therapies Congress 2025, held in London. Ibon ...

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

“Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII ...

Based on early Phase I/II data, investigators at Cincinnati Children's are enrolling more patients with a telomere biology ...

Results from the single-arm open-label trial have been able to elicit an extension of CD34+ cells ex vivo in two out of the 12 patients enrolled on the trial. The trial data, published in the New ...

present an important study that applied a high-resolution transposon-based barcoding system to show the clonal contribution of hematopoietic stem and ...

Alveolar bone resorption (ABR) is a key pathological manifestation in the development of apical periodontitis (AP) that contributes to the AP-associated tooth loss, and whose underlying mechanism ...

Angiofibroma is a benign but potentially locally aggressive vascular tumor that typically originates in the nasopharynx. The etiology of Juvenile Nasopharyngeal Angiofibroma (JNA) is not completely ...

Leukaemia is a type of blood cancer, which starts in blood-forming tissue, such as the bone marrow, and causes large numbers of immature blood cells to be produced and enter the bloodstream ...